Amyloid-beta protein accumulation in the brain, manifesting as plaques, is a hallmark pathological feature of Alzheimer’s disease. Traditionally, the burden of amyloid deposition has been closely linked to clinical symptoms of cognitive decline and to the presence of the APOE ε4 allele—a potent genetic risk factor for late-onset Alzheimer’s. However, the USC-led study reveals that these relationships manifest differently in Hispanic populations compared to non-Hispanic whites. Despite having cognitive impairment or carrying APOE ε4, Hispanic participants generally showed lower amyloid levels, suggesting alternative or additional mechanisms may contribute to dementia risk and progression in this group.

Central to this study’s success was the innovative use of the Global Alzheimer’s Association Interactive Network (GAAIN), a powerful data-sharing platform developed at Stevens INI. GAAIN enables researchers worldwide to harmonize and analyze large-scale Alzheimer’s datasets, overcoming longstanding barriers posed by heterogeneity in imaging technology, tracers, and data acquisition methods. The platform facilitated the integration of amyloid PET imaging data standardized using the Centiloid scale—an analytical tool designed to normalize amyloid burden measurements across different scanners and imaging protocols—allowing for unprecedented cross-cohort comparisons.

The research consortium amalgamated data from five prominent sources, including the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease study, the Alzheimer’s Disease Neuroimaging Initiative, and the Health and Aging Brain Study–Health Disparities among others. This meta-analytic approach enabled comprehensive examination of amyloid burden across a racially and ethnically diverse sample, encompassing a wide clinical spectrum from normal cognition to dementia. The depth and breadth of this database allowed for refined statistical analyses that accounted for confounding factors such as age, sex, level of education, and cognitive performance.

Investigators utilized the Centiloid scale as a unifying metric to quantitatively assess amyloid load. This scale transforms heterogeneous imaging data into standardized units, facilitating direct comparisons across multi-site studies that previously lacked uniformity. By employing such quantitative rigor, the team demonstrated that while amyloid positivity correlated strongly with cognitive impairment overall, Hispanic individuals displayed a distinct profile characterized by comparatively lower amyloid deposition at equivalent levels of cognitive deficit, even when carrying the APOE ε4 allele.

Genetic analyses further illuminated the complexity of disease risk. Although APOE ε4 status increased amyloid positivity in both Hispanic and non-Hispanic white participants, the strength of this association was markedly attenuated in Hispanic cohorts. Specifically, non-Hispanic white carriers had over a fourfold increased likelihood of amyloid pathology, whereas this risk was approximately two and a half times in Hispanic carriers. These differential risks suggest that genetic and environmental contexts modulate Alzheimer’s pathophysiology in a population-specific manner.

Importantly, the study cautions against simplistic interpretations that lower amyloid levels imply lower dementia risk in Hispanic populations. In fact, epidemiological data shows that Hispanic adults experience a disproportionate burden of dementia. The researchers propose that the pathogenesis in these populations may be driven by a confluence of factors beyond amyloid accumulation, including vascular comorbidities, social determinants of health, and potentially other as-yet-unidentified biological processes. This underscores the need for multi-dimensional investigative frameworks.

As anti-amyloid therapies emerge as frontline interventions in Alzheimer’s management, understanding population-level variability in amyloid pathology is paramount. Treatments targeting amyloid may yield differential efficacy, and precision medicine approaches must account for the heterogeneity elucidated by this study. Tailoring interventions based on nuanced biomarker profiles and genetic backgrounds could enhance therapeutic outcomes and equity in clinical care.

The study authors emphasize the necessity for further research with larger, more detailed Hispanic cohorts. Granular data on Hispanic ancestry and longitudinal follow-up will be critical to decipher the dynamics of amyloid deposition and cognitive decline. Additionally, incorporating assessments of vascular health and other metabolic factors may clarify contributors to the divergent amyloid-cognition relationships observed.

Stevens INI director Arthur W. Toga highlights the transformative potential of open data platforms like GAAIN for accelerating Alzheimer’s research across historically underrepresented populations. By fostering collaboration and data integration, these resources enable scientists to capture the biological complexity of dementia and propel the development of innovative, inclusive treatment paradigms.

In summary, this extensive meta-analysis not only challenges conventional paradigms regarding amyloid pathology and genetic risk in Alzheimer’s disease but also advocates for a broader, more inclusive scientific lens. As the global population ages and diversifies, such insights will be essential to addressing the multifaceted challenges of dementia care and research.

Subject of Research: People
Article Title: Association of cognitive impairment and APOE ε4 with Centiloids in Hispanic and non-Hispanic White cohorts
News Publication Date: 11-Jun-2026
Web References: https://ini.usc.edu, https://gaain.org
References: Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, DOI: 10.1002/alz.71586
Image Credits: Stevens INI
Keywords: Alzheimer disease, Neuroscience, Genetics, Aging populations

The focus of this comprehensive investigation was the accumulation of tau, a protein closely linked with Alzheimer’s disease progression. The study utilized state-of-the-art positron emission tomography (PET) imaging with a newly developed tau tracer to detect abnormal tau protein tangles in the brains of over 1,500 cognitively normal and mildly impaired older adults. Notably, this cohort was racially and ethnically diverse, encompassing Black, Hispanic, and non-Hispanic white participants, which allowed for a robust analysis of the influence of ethnoracial identity on Alzheimer’s biomarkers.

Results indicated that Black and Hispanic individuals exhibited significantly higher tau burden in key memory-associated regions of the medial temporal lobe compared to non-Hispanic white participants, even in the absence of overt amyloid plaque buildup, which is traditionally considered the hallmark initiating event in Alzheimer’s pathology. This dissociation between amyloid and tau pathology among different groups disrupts the conventionally understood sequence of biomarker development and suggests alternative disease trajectories may be operative in diverse populations.

Furthermore, the relationship between biological markers and cognitive performance revealed complex interactions. While elevated tau correlated with impaired memory across the cohort, the interplay between amyloid plaque levels and memory decline was only evident in non-Hispanic white and Hispanic groups. Remarkably, in Black participants, amyloid levels did not strengthen the association between tau pathology and memory deficits. This finding implies that other, perhaps non-neuropathological, factors might be more influential in cognitive deterioration within this population.

Experts propose that beyond amyloid and tau pathology, additional elements such as vascular health comorbidities, chronic stress exposure, social determinants of health, and other systemic conditions could be driving memory decline in Black adults. This multifactorial influence necessitates a multidisciplinary approach integrating neurobiology, epidemiology, and social sciences to address Alzheimer’s disease in a clinically meaningful way across all communities.

The research also identified potential technical limitations associated with the tau PET tracer used. The imaging agent occasionally produced signals emanating from adjacent brain regions, confounding the interpretation of tau accumulation patterns. This observation underscores the imperative for rigorous validation of neuroimaging tools in heterogeneous populations to ensure the biological accuracy and reliability of PET data, preventing misinterpretation that could misguide diagnostic or therapeutic decisions.

This study, emerging from the Health and Aging Brain Study–Health Disparities (HABS-HD), represents one of the most extensive neuroimaging efforts targeting Alzheimer’s-related brain changes in racially and ethnically diverse aging populations within the United States. The success of this endeavor owes much to the advanced imaging infrastructure at Stevens INI, which facilitated high-resolution PET imaging and comprehensive data analysis.

Principal investigators emphasize that these findings carry profound implications for precision medicine in Alzheimer’s disease. A one-size-fits-all biomarker framework may inadvertently overlook distinctive pathophysiological mechanisms encountered in different ethnoracial groups. Consequently, clinical trials, diagnostic criteria, and therapeutic strategies must be recalibrated to accommodate biological variability shaped by genetic background, environment, and socio-cultural influences.

Importantly, the data advocate for longitudinal follow-up to dissect how tau, amyloid, vascular function, genetics—including the presence of the APOEε4 allele—and social determinants coalesce over time to influence cognitive trajectories. Such prolonged observation will be instrumental in unraveling the intricate web of contributory factors and optimizing prevention and intervention approaches tailored to diverse populations.

Moreover, the study’s revelations about non-amyloid influences on cognitive decline in Black adults spotlights the pressing need to investigate comorbid conditions and life-course exposures that may exacerbate or mimic Alzheimer’s symptoms. This integrative understanding is critical to avoid misdiagnosis and to design effective treatments that address the broader health context of patients.

The research team strongly advocates for the expansion of neuroimaging studies to encompass a wider array of communities historically underrepresented in Alzheimer’s research. Achieving true equity in neuroscientific inquiry will not only improve diagnostic sensitivity but also enhance the validity and generalizability of scientific findings, ultimately benefiting global populations afflicted by dementia.

In conclusion, this landmark study redefines the landscape of Alzheimer’s disease research by illustrating the heterogeneity in biomarker expression across ethnoracial groups. It challenges entrenched paradigms and sets the stage for a new era in which Alzheimer’s pathology is understood through the lens of diversity. Future efforts must continue to unravel these complex biological and social interdependencies to pave the way for personalized, equitable diagnostic and therapeutic solutions.

Subject of Research: People

Article Title: The relationships between ethnoracial identity, Aβ positivity, APOEε4, and medial temporal lobe tau PET

News Publication Date: 4-Mar-2026

Web References:

• Stevens INI
• Alzheimer’s & Dementia Journal Article
• HABS-HD Study
• Related Animation

References:
10.1002/alz.71226

Image Credits: USC/Stevens INI

Keywords: Alzheimer disease, Tau proteins, Amyloid hypothesis, Amyloidosis, Dementia, Human brain, Brain, Positron emission tomography